
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
Beauty Health's strong 4Q23 performance, reporting revenue of $96.8 million, exceeded both prior internal estimates and street expectations, suggesting robust demand for its product offerings. The company achieved a significant increase in average selling price (ASP) for total systems, rising approximately 20% quarter-over-quarter to $28.8K, which reflects a favorable channel mix with an increased percentage of direct sales. Additionally, the growth in consumables contributed positively to revenue, indicating a promising trajectory for Beauty Health's overall financial performance despite the back-end weighted EBITDA guidance.
Bears say
Beauty Health's stock outlook is negatively impacted by a significant decline in new placements of core delivery systems, which fell over 30% year-over-year and quarter-over-quarter, falling short of earlier projections. This deceleration in growth raises concerns regarding future consumable sales, which are essential for achieving management's profitability targets in 2024. Furthermore, management's revenue and adjusted EBITDA guidance for the first quarter of 2024 indicates a solid miss compared to prior estimates, suggesting potential difficulties in meeting full-year performance goals.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares